NCCN Guidelines for Thyroid Carcinoma V.1.

2018 – Web teleconference on 10/13/17

Guideline Page Panel Discussion/References Institution Vote

and Request
YES NO ABSTAIN ABSENT

PAP-9, FOLL-9 and
HÜRT-9
Internal request:
Institutional Review
comment to consider the
inclusion of dabrafenib
(BRAF-positive) to the list
of other small-molecule
kinase inhibitors.
Based on the panel discussion of available data, the panel consensus was to 13 0 1 13
include dabrafenib as a treatment option for BRAF mutation-positive disease in a
footnote of other small-molecule kinase inhibitors: "While not FDA approved for
treatment of differentiated thyroid cancer, commercially available small-molecule
kinase inhibitors (such as axitinib, everolimus, pazopanib, sunitinib, vandetanib,
vemurafenib (BRAF-positive), dabrafenib (BRAF-positive) or cabozantinib [all are
category 2A]) can be considered if clinical trials are not available or appropriate.”
Falchook GS, et al. BRAF inhibitor dabrafenib in patients with metastatic BRAF-
mutant thyroid cancer. Thyroid 2015;25(1):71-77.

Shah MH, et al. Results of randomized phase II trial of dabrafenib versus

dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma
[abstract]. J Clin Oncol 2017;35:15_suppl, 6022-6022.

PAP-9, PAP-10, FOLL-9, Based on a review of data and discussion, the panel consensus did not support 0 12 2 13
10, HÜRT-9, 10, MEDU-7, the addition of pembrolizumab as a systemic therapy treatment option for
ANAP-2, and ANAP-A papillary, follicular, Hürthle, medullary, and anaplastic thyroid carcinoma into the
Guidelines [due to insufficient available data for thyroid carcinoma].
External request:
Submission from Merck & See submission for references
Co. to review the enclosed
data for the inclusion
pembrolizumab as a
systemic therapy treatment
option for unresectable or
metastatic microsatellite
instability high (MSI-H) or
deficient mismatch repair
(dMMR) solid tumors that
have progressed following
prior treatment and have no
satisfactory alternative
treatment options.

5.23.18